These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 16563985)

  • 1. Pirfenidone and chronic progressive obliterative airway disease.
    Dosanjh A
    J Heart Lung Transplant; 2006 Apr; 25(4):490. PubMed ID: 16563985
    [No Abstract]   [Full Text] [Related]  

  • 2. Pirfenidone inhibits obliterative airway disease in mouse tracheal allografts.
    Zhou H; Latham CW; Zander DS; Margolin SB; Visner GA
    J Heart Lung Transplant; 2005 Oct; 24(10):1577-85. PubMed ID: 16210133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pirfenidone: anti-fibrotic agent with a potential therapeutic role in the management of transplantation patients.
    Dosanjh A
    Eur J Pharmacol; 2006 May; 536(3):219-22. PubMed ID: 16581063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tacrolimus treatment effectively inhibits progression of obliterative airway disease even at later stages of disease development.
    Hollmén M; Tikkanen JM; Nykänen AI; Koskinen PK; Lemström KB
    J Heart Lung Transplant; 2008 Aug; 27(8):856-64. PubMed ID: 18656798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pirfenidone: A novel anti-fibrotic agent and progressive chronic allograft rejection.
    Dosanjh A; Ikonen T; Wan B; Morris RE
    Pulm Pharmacol Ther; 2002; 15(5):433-7. PubMed ID: 12406665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The novel antifibrotic agent pirfenidone attenuates the profibrotic environment generated by calcineurin inhibitors in the rat salt-depletion model.
    Brook NR; Waller JR; Bicknell GR; Nicholson ML
    Transplant Proc; 2005; 37(1):130-3. PubMed ID: 15808571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pirfenidone: a potential therapy for progressive lung allograft dysfunction?
    Ihle F; von Wulffen W; Neurohr C
    J Heart Lung Transplant; 2013 May; 32(5):574-5. PubMed ID: 23453574
    [No Abstract]   [Full Text] [Related]  

  • 8. FK778 and tacrolimus prevent the development of obliterative airway disease after heterotopic rat tracheal transplantation.
    Deuse T; Schrepfer S; Koch-Nolte F; Haddad M; Schwedhelm E; Böger R; Schäfer H; Detter C; Reichenspurner H
    J Heart Lung Transplant; 2005 Nov; 24(11):1844-54. PubMed ID: 16297791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pirfenidone: a potential therapeutic option in the treatment of liver fibrosis.
    Grizzi F
    Clin Exp Pharmacol Physiol; 2009 Oct; 36(10):961-2. PubMed ID: 19650793
    [No Abstract]   [Full Text] [Related]  

  • 10. Pirfenidone: a novel antifibrotic agent with implications for the treatment of obliterative bronchiolitis.
    Dosanjh AK; Wan B; Throndset W; Sherwood S; Morris RE
    Transplant Proc; 1998 Aug; 30(5):1910-1. PubMed ID: 9723329
    [No Abstract]   [Full Text] [Related]  

  • 11. [Establishment of obliterative bronchiolitis in allo-trachea transplant model of rat and detection of its pathogenesis preliminarily].
    Qi Z; Yang DY; Wang R; Wang SZ; Ping YM
    Zhonghua Wai Ke Za Zhi; 2007 Feb; 45(4):262-6. PubMed ID: 17502025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pirfenidone: a novel potential therapeutic agent in the management of chronic allograft rejection.
    Dosanjh A
    Transplant Proc; 2007 Sep; 39(7):2153-6. PubMed ID: 17889122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhaled cyclosporine in lung transplantation.
    Verleden GM; Dupont LJ
    N Engl J Med; 2006 Apr; 354(16):1752-3; author reply 1752-3. PubMed ID: 16625016
    [No Abstract]   [Full Text] [Related]  

  • 14. A comparison of factors associated with collagen metabolism in different skeletal muscles from dystrophic (mdx) mice: impact of pirfenidone.
    Gosselin LE; Williams JE; Personius K; Farkas GA
    Muscle Nerve; 2007 Feb; 35(2):208-16. PubMed ID: 17058274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pilot study in patients with established advanced liver fibrosis using pirfenidone.
    Armendáriz-Borunda J; Islas-Carbajal MC; Meza-García E; Rincón AR; Lucano S; Sandoval AS; Salazar A; Berumen J; Alvarez A; Covarrubias A; Aréchiga G; García L
    Gut; 2006 Nov; 55(11):1663-5. PubMed ID: 17047115
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of topical application of pirfenidone ointment on thermoplasty-induced acute lameness in a double-blind and acute and chronic lameness of musculoskeletal origin in an open multi-centered field trial in horses.
    Giri SN; Margolin SB
    Res Commun Mol Pathol Pharmacol; 2005; 117-118():47-63. PubMed ID: 18426078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel pirfenidone analogues: synthesis of pyridin-2-ones for the treatment of pulmonary fibrosis.
    Ammar YA; Ismail MM; El-Sehrawi HM; Noaman E; Bayomi AH; Shawer TZ
    Arch Pharm (Weinheim); 2006 Aug; 339(8):429-36. PubMed ID: 16832818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Attenuation of airway obliteration by ciprofloxacin in experimental posttransplant bronchiolitis obliterans.
    Remund K; Rechsteiner T; Rentsch K; Vogt P; Russi EW; Boehler A
    Transplantation; 2008 Mar; 85(5):726-31. PubMed ID: 18337667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pirfenidone treatment in idiopathic pulmonary fibrosis: too much of a great expectation?
    Papiris SA; Kagouridis K; Kolilekas L; Triantafillidou C; Tsangaris I; Manali ED
    Eur Respir J; 2012 Sep; 40(3):794-5. PubMed ID: 22941551
    [No Abstract]   [Full Text] [Related]  

  • 20. Trials and tribulations of new agents, novel biomarkers, and retarding renal progression.
    Levin A; Beaulieu MC
    J Am Soc Nephrol; 2011 Jun; 22(6):992-3. PubMed ID: 21617124
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.